Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Kantarjian, H' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 326 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Nguyen, Q; Estey, E; Raad, I; Rolston, K; Kantarjian, H; Jacobson, K; Konoplev, S; Ghosh, S; Luna, M; Tarrand, J; Whimbey, E
      Cytomegalovirus pneumonia in adults with leukemia: An emerging problem

      CLINICAL INFECTIOUS DISEASES
    2. Estey, E; Koller, C; Cortes, J; Reed, P; Freireich, E; Giles, F; Kantarjian, H
      Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid

      LEUKEMIA & LYMPHOMA
    3. Verstovsek, S; Estey, E; Manshouri, T; Keating, M; Kantarjian, H; Giles, FJ; Albitar, M
      High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome

      LEUKEMIA & LYMPHOMA
    4. Rosenfeld, C; Kantarjian, H
      Is myelodysplastic related acute myelogenous leukemia a distinct entity from de novo acute myelogenous leukemia? Potential for targeted therapies

      LEUKEMIA & LYMPHOMA
    5. Giles, FJ; Kantarjian, H; O'Brien, S; Rios, MB; Cortes, J; Beran, M; Koller, C; Keating, M; Talpaz, M
      Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with Philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase

      LEUKEMIA & LYMPHOMA
    6. Tannir, NM; Kantarjian, H
      Idiopathic thrombocytopenic purpura following successful treatment of acute lymphoblastic leukemia

      LEUKEMIA & LYMPHOMA
    7. Di Raimondo, F; Giustolisi, R; Lerner, S; Cacciola, E; O'Brien, S; Kantarjian, H; Keating, MJ
      Retrospective study of the prognostic role of serum thymidine kinase levelin CLL patients with active disease treated with fludarabine

      ANNALS OF ONCOLOGY
    8. Verstovsek, S; Kantarjian, H; Estey, E; Aguayo, A; Giles, FJ; Manshouri, T; Koller, C; Estrov, Z; Freireich, E; Keating, M; Albitar, M
      Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome

      LEUKEMIA
    9. Sarriera, JE; Albitar, M; Estrov, Z; Gidel, C; Aboul-Nasr, R; Manshouri, T; Kornblau, S; Chang, KS; Kantarjian, H; Estey, E
      Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing

      LEUKEMIA
    10. Verstovsek, S; Manshouri, T; Kantarjian, H; Giles, FJ; Keating, M; Estey, E; Albitar, M
      Highly reproducible detection and semi-quantification of telomerase activity

      BIOTECHNIQUES
    11. O'Brien, SM; Kantarjian, H; Thomas, DA; Giles, FJ; Freireich, EJ; Cortes, J; Lerner, S; Keating, MJ
      Rituximab dose-escalation trial in chronic lymphocytic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    12. Soignet, SL; Frankel, SR; Douer, D; Tallman, MS; Kantarjian, H; Calleja, E; Stone, RM; Kalaycio, M; Scheinberg, DA; Steinherz, P; Sievers, EL; Coutre, S; Dahlberg, S; Ellison, R; Warrell, RP
      United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    13. Kurzrock, R; Bueso-Ramos, CE; Kantarjian, H; Freireich, E; Tucker, SL; Siciliano, M; Pilat, S; Talpaz, M
      BCR rearrangement-negative chronic myelogenous leukemia revisited

      JOURNAL OF CLINICAL ONCOLOGY
    14. Ravandi, F; Kantarjian, H; Cohen, A; Davis, M; O'Brien, S; Anderlini, P; Andersson, B; Claxton, D; Donato, M; Gajewski, J; Khouri, I; Korbling, M; Ueno, N; deVos, D; Champlin, R; Giralt, S
      Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study

      BONE MARROW TRANSPLANTATION
    15. Giles, F; Cortes, J; Garcia-Manero, G; Kornblau, S; Estey, E; Kwari, M; Murgo, A; Kantarjian, H
      Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia

      INVESTIGATIONAL NEW DRUGS
    16. Aguayo, A; Manshouri, T; O'Brien, S; Keating, M; Beran, M; Koller, C; Kantarjian, H; Rogers, A; Albitar, M
      Clinical relevance of Flt1 and Tie1 angiogenesis receptors expression in B-cell chronic lymphocytic leukemia (CLL)

      LEUKEMIA RESEARCH
    17. Kalidas, MT; Kantarjian, H; Talpaz, M
      Chronic myelogenous leukemia

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    18. Druker, BJ; Talpaz, M; Resta, DJ; Peng, B; Buchdunger, E; Ford, JM; Lydon, NB; Kantarjian, H; Capdeville, R; Ohno-Jones, S; Sawyers, CL
      Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinasein chronic myeloid leukemia.

      NEW ENGLAND JOURNAL OF MEDICINE
    19. Druker, BJ; Sawyers, CL; Kantarjian, H; Resta, DJ; Reese, SF; Ford, JM; Capdeville, R; Talpaz, M
      Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia withthe philadelphia chromosome.

      NEW ENGLAND JOURNAL OF MEDICINE
    20. Laurent, E; Talpaz, M; Kantarjian, H; Kurzrock, R
      The BCR gene and Philadelphia chromosome-positive leukemogenesis

      CANCER RESEARCH
    21. Beran, M; Shen, Y; Kantarjian, H; O'Brien, S; Koller, CA; Giles, FJ; Cortes, J; Thomas, DA; Faderl, S; Despa, S; Estey, EH
      High-dose chemotherapy in high-risk myelodysplastic syndrome - Covariate-adjusted comparison of five regimens

      CANCER
    22. Cortes, J; O'Brien, S; Loscertales, J; Kantarjian, H; Giles, F; Thomas, D; Koller, C; Keating, M
      Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia

      CANCER
    23. Cortes, J; Estey, E; O'Brien, S; Giles, F; Shen, Y; Koller, C; Beran, M; Thomas, D; Keating, M; Kantarjian, H
      High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia

      CANCER
    24. Verstovsek, S; Kantarjian, H; Aguayo, A; Manshouri, T; Freireich, E; Keating, M; Estey, E; Albitar, M
      Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome

      BRITISH JOURNAL OF HAEMATOLOGY
    25. Pachmann, K; Zhao, SR; Schenk, T; Kantarjian, H; El-Naggar, AK; Siciliano, MJ; Guo, JQ; Arlinghaus, RB; Andreeff, M
      Expression of bcr-abl mRNA in individual chronic myelogenous leukaemia cells as determined by in situ amplification

      BRITISH JOURNAL OF HAEMATOLOGY
    26. Cheson, BD; Bennett, JM; Kantarjian, H; Schiffer, CA; Nimer, SD; Lowenberg, B; Stone, RM; Mittelman, M; Sanz, GF; Wijermans, PW; Greenberg, PL
      Response: Myelodysplastic syndromes standardized response criteria: further definition

      BLOOD
    27. Donato, NJ; Wu, JY; Zhang, L; Kantarjian, H; Talpaz, M
      Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulatingfactor receptor beta-chain in BCR-ABL(+) human leukemic cells: associationwith loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition

      BLOOD
    28. Kornblau, SM; Vu, HT; Ruvolo, P; Estrov, Z; O'Brien, S; Cortes, J; Kantarjian, H; Andreeff, M; May, WS
      BAX and PKC alpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia

      CLINICAL CANCER RESEARCH
    29. Vey, N; Giles, FJ; Kantarjian, H; Smith, TL; Beran, M; Jeha, S
      The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia

      CLINICAL CANCER RESEARCH
    30. Rodriguez, J; Cortes, J; Talpaz, M; O'Brien, S; Smith, TL; Rios, MB; Kantarjian, H
      Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia

      CLINICAL CANCER RESEARCH
    31. Keating, MJ; Smith, TL; Lerner, S; O'Brien, S; Robertson, LE; Kantarjian, H; Freireich, EJ
      Prediction of prognosis following fludarabine used as secondary therapy for chronic lymphocytic leukemia

      LEUKEMIA & LYMPHOMA
    32. Cortes, J; Estey, E; Beran, M; O'Brien, S; Giles, F; Koller, C; Keating, M; Kantarjian, H
      Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia

      LEUKEMIA & LYMPHOMA
    33. Rodriguez, J; McLaughlin, P; Fayad, L; Santiago, M; Hess, M; Rodriguez, MA; Romaguera, J; Hagemeister, F; Kantarjian, H; Cabanillas, F
      Follicular large cell lymphoma: Long-term follow-up of 62 patients treatedbetween 1973-1981

      ANNALS OF ONCOLOGY
    34. Sarris, AH; Hagemeister, F; Romaguera, J; Rodriguez, MA; McLaughlin, P; Tsimberidou, AM; Medeiros, LJ; Samuels, B; Pate, O; Oholendt, M; Kantarjian, H; Burge, C; Cabanillas, F
      Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial

      ANNALS OF ONCOLOGY
    35. Talpaz, M; Berman, E; Clift, RA; Copelan, EA; Emanuel, PD; Erba, HP; Glenn, MJ; Greenberg, PL; Jones, RJ; O'Brien, S; Saba, HI; Schilder, R; Snyder, DS; Soiffer, RJ; Tallman, MS; Wetzler, M; Ravandi-Kashani, F; Kantarjian, H; Talpaz, M
      NCCN Practice Guidelines for chronic myelogenous leukemia

      ONCOLOGY-NEW YORK
    36. Talpaz, M; Qiu, X; Cheng, K; Cortes, JE; Kantarjian, H; Kurzrock, R
      Autoantibodies to Abl and Bcr proteins

      LEUKEMIA
    37. Seong, CM; Giralt, S; Kantarjian, H; Xu, JP; Swantkowski, J; Hayes, K; Glassman, AB; Khouri, I; Korbling, M; Thall, P; Siciliano, MJ; Champlin, RE
      Early detection of relapse by hypermetaphase fluorescence in situ hybridization after allogeneic bone marrow transplantation for chronic myeloid leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    38. Ravandi-Kashani, F; O'Brien, S; Manshouri, T; Lerner, S; Sim, S; Dodd, K; Kantarjian, H; Freireich, E; Keating, M; Albitar, M
      Variations in the low levels of cyclin D1/BCL1 have prognostic value in chronic lymphocytic leukemia

      LEUKEMIA RESEARCH
    39. Keyhani, A; Huh, YO; Jendiroba, D; Pagliaro, L; Cortez, J; Pierce, S; Pearlman, M; Estey, E; Kantarjian, H; Freireich, EJ
      Increased CD38 expression is associated with favorable prognosis in adult acute leukemia

      LEUKEMIA RESEARCH
    40. Kozuch, P; Talpaz, M; Faderl, S; O'Brien, S; Freireich, EJ; Kantarjian, H
      Avascular necrosis of the femoral head in chronic myeloid leukemia patients treated with interferon-alpha - A synergistic correlation?

      CANCER
    41. Chung, CY; Kantarjian, H; Haidar, M; Starostik, P; Manshouri, T; Gidel, C; Freireich, E; Keating, M; Albitar, M
      Deletions in the 13q14 locus in adult lymphoblastic leukemia - Rate of incidence and relevance

      CANCER
    42. Haidar, MA; Kantarjian, H; Manshouri, T; Chang, CY; O'Brien, S; Freireich, E; Keating, M; Albitar, M
      ATM gene deletion in patients with adult acute lymphoblastic leukemia

      CANCER
    43. Kaban, K; Kantarjian, H; Talpaz, M; O'Brien, S; Cortes, J; Giles, FJ; Pierce, S; Albitar, M
      Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia - Correlation with disease progression and response to therapy

      CANCER
    44. Aguayo, A; Kantarjian, H; Manshouri, T; Gidel, C; Estey, E; Thomas, D; Koller, C; Estrov, Z; O'Brien, S; Keating, M; Freireich, E; Albitar, M
      Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes

      BLOOD
    45. Aguayo, A; O'Brien, S; Keating, M; Manshouri, T; Gidel, C; Barlogie, B; Beran, M; Koller, C; Kantarjian, H; Albitar, M
      Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia

      BLOOD
    46. Cheson, BD; Bennett, JM; Kantarjian, H; Pinto, A; Schiffer, CA; Nimer, SD; Lowenberg, B; Beran, M; de Witte, TM; Stone, RM; Mittelman, M; Sanz, GF; Wijermans, PW; Gore, S; Greenberg, PL
      Report of an international working group to standardize response criteria for myelodysplastic syndromes

      BLOOD
    47. Albitar, M; Beran, M; O'Brien, S; Kantarjian, H; Frieriech, E; Keating, M; Estey, E
      Differences between refractory anemia with excess blasts in transformationand acute myeloid leukemia

      BLOOD
    48. Faber, J; Kantarjian, H; Roberts, WM; Keating, M; Freireich, E; Albitar, M
      Terminal deoxynucleotidyl transferase-negative acute lymphoblastic leukemia

      ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
    49. Cortes, J; Fayad, L; O'Brien, S; Keating, M; Kantarjian, H
      Persistence of peripheral blood and bone marrow blasts during remission induction in adult acute lymphoblastic leukemia confers a poor prognosis depending on treatment intensity

      CLINICAL CANCER RESEARCH
    50. Kornblau, SM; Thall, PF; Estrov, Z; Walterscheid, M; Patel, S; Theriault, A; Keating, MJ; Kantarjian, H; Estey, E; Andreeff, M
      The prognostic impact of BCL2 protein expression in acute myelogenous leukemia varies with cytogenetics

      CLINICAL CANCER RESEARCH
    51. Partyka, S; O'Brien, S; Podoloff, D; Kantarjian, H; Keating, MJ
      The usefulness of high dose (7-10mci) gallium (Ga-67) scanning to diagnoseRichter's transformation

      LEUKEMIA & LYMPHOMA
    52. Ravandi-Kashani, F; Cortes, J; Cohen, P; Talpaz, M; O'Brien, S; Markowitz, A; Kantarjian, H
      Cutaneous ulcers associated with hydroxyurea therapy in myeloproliferativedisorders

      LEUKEMIA & LYMPHOMA
    53. Vey, N; Kantarjian, H; Tran, H; Beran, M; O'Brien, S; Bivins, C; Giles, F; Cortes, J; Cheson, B; Arbuck, S; Estey, E
      Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia

      ANNALS OF ONCOLOGY
    54. Khouri, IF; Lee, MS; Romaguera, J; Mirza, N; Kantarjian, H; Korbling, M; Albitar, M; Giralt, S; Samuels, B; Anderlini, P; Rodriguez, J; von Wolff, B; Gajewski, J; Cabanillas, F; Champlin, R
      Allogeneic hematopoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy

      ANNALS OF ONCOLOGY
    55. Estey, EH; Thall, PF; Reed, P; Kantarjian, H; Beran, M; Pierce, S; Keating, MJ
      Treatment of newly diagnosed AML, RAEB-t or RAEB with lisofylline or placebo in addition to chemotherapy

      LEUKEMIA
    56. Patmasiriwat, P; Fraizer, G; Kantarjian, H; Saunders, GF
      WT1 and GATA1 expression in myelodysplastic syndrome and acute leukemia

      LEUKEMIA
    57. Beran, M; Estey, E; O'Brien, S; Cortes, J; Koller, CA; Giles, FJ; Kornblau, S; Andreeff, M; Vey, N; Pierce, SR; Hayes, K; Wong, GC; Keating, M; Kantarjian, H
      Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    58. Thomas, DA; Cortes, J; O'Brien, S; Pierce, S; Faderl, S; Albitar, M; Hagemeister, FB; Cabanillas, FF; Murphy, S; Keating, MJ; Kantarjian, H
      Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    59. Cortes, J; O'Brien, S; Estey, E; Giles, F; Keating, M; Kantarjian, H
      Phase I study of liposomal daunorubicin in patients with acute leukemia

      INVESTIGATIONAL NEW DRUGS
    60. Vey, N; Kantarjian, H; Beran, M; O'Brien, S; Cortes, J; Koller, C; Estey, E
      Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: Results of a randomized phase I/II study

      INVESTIGATIONAL NEW DRUGS
    61. Starostik, P; O'Brien, S; Chung, CY; Haidar, M; Manshouri, T; Kantarjian, H; Freireich, E; Keating, M; Albitar, M
      The prognostic significance of 13q14 deletions in chronic lymphocytic leukemia

      LEUKEMIA RESEARCH
    62. Albitar, M; Manshouri, T; Kantarjian, H; Keating, M; Estrov, Z; Faber, J; Freireich, EJ; Pierce, S; Estey, E
      Correlation between lower c-mpl protein expression and favorable cytogenetic groups in acute myeloid leukemia

      LEUKEMIA RESEARCH
    63. Albitar, M; Chang, KS; Pierce, S; Kantarjian, H; Estey, E
      The short form of PML-RAR alpha fusion transcript is associated with poor survival

      LEUKEMIA RESEARCH
    64. Kantarjian, H
      Introduction: Hematologic malignancies: Is there a role for topoisomerase-I inhibitors?

      SEMINARS IN HEMATOLOGY
    65. Beran, M; Kantarjian, H
      Results of topotecan-based combination therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia

      SEMINARS IN HEMATOLOGY
    66. Kantarjian, H
      New developments in the treatment of acute myeloid leukemia: Focus on topotecan

      SEMINARS IN HEMATOLOGY
    67. Aguayo, A; Cortes, J; Thomas, D; Pierce, S; Keating, M; Kantarjian, H
      Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia

      CANCER
    68. Thomas, DA; Kantarjian, H; Smith, TL; Koller, C; Cortes, J; O'Brien, S; Giles, FJ; Gajewski, J; Pierce, S; Keating, MJ
      Primary refractory and relapsed adult acute lymphoblastic leukemia - Characteristics, treatment results, and prognosis with salvage therapy

      CANCER
    69. Estey, EH; Giles, FJ; Kantarjian, H; O'Brien, S; Cortes, J; Freireich, EJ; Lopez-Berestein, G; Keating, M
      Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia

      BLOOD
    70. Aguayo, A; Estey, E; Kantarjian, H; Mansouri, T; Gidel, C; Keating, M; Giles, F; Estrov, Z; Barlogie, B; Albitar, M
      Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia

      BLOOD
    71. Estey, EH; Thall, PF; Pierce, S; Cortes, J; Beran, M; Kantarjian, H; Keating, MJ; Andreeff, M; Freireich, E
      Randomized phase II study of fludarabine plus cytosine arabinoside plus idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome

      BLOOD
    72. Issa, JPJ; Kantarjian, H; Mohan, A; O'Brien, S; Cortes, J; Pierce, S; Talpaz, M
      Methylation of the ABL1 promoter in chronic myelogenous leukemia: Lack of prognostic significance

      BLOOD
    73. O'Brien, S; Kantarjian, H; Koller, C; Feldman, E; Beran, M; Andreeff, M; Giralt, S; Cheson, B; Keating, M; Freireich, E; Rios, MB; Talpaz, M
      Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia

      BLOOD
    74. Lin, CW; O'Brien, S; Faber, J; Manshouri, T; Romaguera, J; Huh, YO; Kantarjian, H; Keating, M; Albitar, M
      De novo CD5(+) Burkitt lymphoma/leukemia

      AJCP. American journal of clinical pathology
    75. TALPAZ M; KURZROCK R; KANTARJIAN H
      THE CLINICAL IMPACT OF INTERFERON USAGE IN HEMATOLOGIC MALIGNANCIES

      European cytokine network
    76. SACCHI S; CORTES J; KANTARJIAN H; TALPAZ M
      EFFECTS OF INTERFERON-ALPHA THERAPY ON LYMPHOCYTE SUBPOPULATIONS IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA

      Hematopathology and molecular hematology
    77. KRAINICK U; KANTARJIAN H; BROUSSARD S; TALPAZ M
      LOCAL CUTANEOUS NECROTIZING LESIONS ASSOCIATED WITH INTERFERON INJECTIONS

      Journal of interferon & cytokine research
    78. KORNBLAU SM; ANDREEFF M; HU SX; XU HJ; PATEL S; THERIAULT A; KOLLER C; KANTARJIAN H; ESTEY E; DEISSEROTH AB; BENEDICT WF
      LOW AND MAXIMALLY PHOSPHORYLATED LEVELS OF THE RETINOBLASTOMA PROTEINCONFER POOR-PROGNOSIS IN NEWLY-DIAGNOSED ACUTE MYELOGENOUS LEUKEMIA -A PROSPECTIVE-STUDY

      Clinical cancer research
    79. BERAN M; CAO XB; ESTROV Z; JEHA S; JIN GZ; OBRIEN S; TALPAZ M; ARLINGHAUS RB; LYDON NB; KANTARJIAN H
      SELECTIVE-INHIBITION OF CELL-PROLIFERATION AND BCR-ABL PHOSPHORYLATION IN ACUTE LYMPHOBLASTIC-LEUKEMIA CELLS EXPRESSING M-R-190,000 BCR-ABLPROTEIN BY A TYROSINE KINASE INHIBITOR (CGP-57148)

      Clinical cancer research
    80. ENGLUND JA; CHAMPLIN RE; WYDE PR; KANTARJIAN H; ATMAR RL; TARRAND J; YOUSUF H; REGNERY H; KLIMOV AI; COX NJ; WHIMBEY E
      COMMON EMERGENCE OF AMANTADINE-RESISTANT AND RIMANTADINE-RESISTANT INFLUENZA-A VIRUSES IN SYMPTOMATIC IMMUNOCOMPROMISED ADULTS

      Clinical infectious diseases
    81. KORNBLAU SM; KANTARJIAN H; OBRIEN S; ANDREEFF M; KOLLER CA; BERAN M; KEATING M; ESTEY E
      CECA-CYCLOPHOSPHAMIDE, ETOPOSIDE, CARBOPLATIN AND CYTOSINE-ARABINOSIDE - A NEW SALVAGE REGIMEN FOR RELAPSED OR REFRACTORY ACUTE MYELOGENOUSLEUKEMIA

      Leukemia & lymphoma
    82. Jeha, S; Kantarjian, H; O'Brien, S; Vitek, L; Beran, M
      Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia

      LEUKEMIA & LYMPHOMA
    83. CORTES J; KANTARJIAN H; OBRIEN S; KURZROCK R; KEATING M; TALPAZ M
      GM-CSF CAN IMPROVE THE CYTOGENETIC RESPONSE OBTAINED WITH INTERFERON-ALPHA THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    84. CORTES J; FAYAD L; KANTARJIAN H; OBRIEN S; LEE MS; TALPAZ M
      ASSOCIATION OF HLA PHENOTYPE AND RESPONSE TO INTERFERON-ALPHA IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA

      Leukemia
    85. GANDHI V; PLUNKETT W; KANTARJIAN H; TALPAZ M; ROBERTSON LE; OBRIEN S
      CELLULAR PHARMACODYNAMICS AND PLASMA PHARMACOKINETICS OF PARENTERALLYINFUSED HYDROXYUREA DURING A PHASE-I CLINICAL-TRIAL IN CHRONIC MYELOGENOUS LEUKEMIA

      Journal of clinical oncology
    86. KURZROCK R; ESTROV Z; KANTARJIAN H; TALPAZ M
      CONVERSION OF INTERFERON-INDUCED, LONG-TERM CYTOGENETIC REMISSIONS INCHRONIC MYELOGENOUS LEUKEMIA TO POLYMERASE-CHAIN-REACTION NEGATIVITY

      Journal of clinical oncology
    87. CORTES J; TALPAZ M; OBRIEN S; RIOS MB; MAJLIS A; KEATING M; FREIREICH EJ; KANTARJIAN H
      SUPPRESSION OF CYTOGENETIC CLONAL EVOLUTION WITH INTERFERON-ALPHA THERAPY IN PATIENTS WITH PHILADELPHIA-CHROMOSOME-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA

      Journal of clinical oncology
    88. Rodriguez, J; Cortes, J; Smith, T; O'Brien, S; Rios, MB; Talpaz, M; Kantarjian, H
      Determinants of prognosis in late chronic-phase chronic myelogenous leukemia

      JOURNAL OF CLINICAL ONCOLOGY
    89. Khouri, IF; Romaguera, J; Kantarjian, H; Palmer, JL; Pugh, WC; Korbling, M; Hagemeister, F; Samuels, B; Rodriguez, A; Giralt, S; Younes, A; Przepiorka, D; Claxton, D; Cabanillas, F; Champlin, R
      Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma

      JOURNAL OF CLINICAL ONCOLOGY
    90. JENDIROBA DB; LICHTIGER B; ANAISSIE E; REDDY V; OBRIEN S; KANTARJIAN H; FREIREICH EJ
      EVALUATION AND COMPARISON OF 3 MOBILIZATION METHODS FOR THE COLLECTION OF GRANULOCYTES

      Transfusion
    91. KANTARJIAN H
      NEW ADVANCES IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES - FOCUS ON TOPOISOMERASE-I INHIBITORS - INTRODUCTION

      Seminars in hematology
    92. BERAN M; KANTARJIAN H
      TOPOTECAN IN THE TREATMENT OF HEMATOLOGIC MALIGNANCIES

      Seminars in hematology
    93. STAROSTIK P; MANSHOURI T; OBRIEN S; FREIREICH E; KANTARJIAN H; HAIDAR M; LERNER S; KEATING M; ALBITAR M
      DEFICIENCY OF THE ATM PROTEIN EXPRESSION DEFINES AN AGGRESSIVE SUBGROUP OF B-CELL CHRONIC LYMPHOCYTIC-LEUKEMIA

      Cancer research
    94. KEATING MJ; OBRIEN S; LERNER S; KOLLER C; BERAN M; ROBERTSON LE; FREIREICH EJ; ESTEY E; KANTARJIAN H
      LONG-TERM FOLLOW-UP OF PATIENTS WITH CHRONIC-LYMPHOCYTIC-LEUKEMIA (CLL) RECEIVING FLUDARABINE REGIMENS AS INITIAL THERAPY

      Blood
    95. RANDHAWA GS; CUI HM; BARLETTA JA; STRICHMANALMASHANU LZ; TALPAZ M; KANTARJIAN H; DEISSEROTH AB; CHAMPLIN RC; FEINBERG AP
      LOSS OF IMPRINTING IN DISEASE PROGRESSION IN CHRONIC MYELOGENOUS LEUKEMIA

      Blood
    96. ANAISSIE EJ; KONTOYIANNIS DP; OBRIEN S; KANTARJIAN H; ROBERTSON L; LERNER S; KEATING MJ
      INFECTIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC-LEUKEMIA TREATED WITHFLUDARABINE

      Annals of internal medicine
    97. DELIMA M; ALBITAR M; OBRIEN S; PIERCE S; KANTARJIAN H; ANDREEFF M; FAYAD L; KEATING M; ESTEY E
      COMPARISON OF REFERRING AND TERTIARY CANCER CENTER PHYSICIANS DIAGNOSES IN PATIENTS WITH LEUKEMIA

      The American journal of medicine
    98. MUNKER R; KANTARJIAN H; OBRIEN S; KEATING M; ANDREEFF M; ESTEY EH
      PHASE-I STUDY OF TAXOL IN REFRACTORY ACUTE MYELOGENOUS LEUKEMIAS USING A WEEKLY SCHEDULE

      Acta haematologica
    99. ALBITAR M; WU WIC; FELTZ E; JIN GH; HIRSCHGINSBERG C; KANTARJIAN H; BERAN M
      SIMPLIFIED REVERSE DOT-BLOT ANALYSES FOR DETECTING RAS ONCOGENE MUTATIONS

      Molecular diagnosis
    100. BERAN M; JEHA S; OBRIEN S; ESTEY E; VITEK L; ZURLO MG; RIOS MB; KEATING M; KANTARJIAN H
      TALLIMUSTINE, AN EFFECTIVE ANTILEUKEMIC AGENT IN A SEVERE COMBINED IMMUNODEFICIENT MOUSE MODEL OF ADULT MYELOGENOUS LEUKEMIA, INDUCES REMISSIONS IN A PHASE-I STUDY

      Clinical cancer research


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 04/06/20 alle ore 11:12:47